Cancer often evades the body’s defenses by suppressing or exhausting immune cells. This funding call supports groundbreaking research into immune reprogramming — restoring dysfunctional cells, reshaping tumor environments, and enhancing anti‑tumor responses through innovative approaches.
Researchers may explore RNA-based technologies, engineered immune cells, cytokine modulation, or computational discovery to identify new therapeutic targets. Projects can focus on cancers with strong immune dysfunction rationales, including HPV‑, EBV‑, HBV‑, HCV‑, and HTLV‑associated malignancies, as well as lung, colorectal, and hematologic cancers.
Expected outputs include predictive biomarkers, datasets mapping immune cell trajectories, translational human models, and novel therapeutic targets. Research must be validated in vivo or ex vivo using disease‑relevant models — studies limited to cell lines or healthy primary cells are not eligible.
Eligible applicants are biomedical researchers worldwide with doctoral degrees, affiliated with nonprofit institutions.
💡 Support available — up to USD 480,000 for projects advancing immune reprogramming in cancer research.
If you already have an active fundsforNGOs Premium Membership, simply log in to access complete details, including eligibility criteria, application guidelines, and deadlines — all in one place.
Not yet renewed your Premium Membership account? Renew Today & Keep Your Premium Edge
